Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

By sjmartinez • December 7, 2023

Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. PMID: 38055253.

Tags: Hematology/Oncology, Publications

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study

Kim YJ, Merle P, Finn RS, Klümpen HJ, Lim HY, Ikeda M, Granito A, Masi G, Gerolami R, Pinter M, Babajanyan S, Twumasi-Ankrah P, Ghadessi[...]

Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance

Markosian C, Buckley CW, Chai-Ho W, Schiller GJ. Differential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance. Leuk[...]

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer

Su Y, Liu C, Lu X, Chuang HY, Li G, Shao S, Kong Y, Lee JW, Ng RH, Wong S, Robert L, Warden C, Liu[...]